Chester County News and Community Website
NEWTON, PA — Traws Pharma, Inc. (NASDAQ: TRAW) is set to host a virtual investor event on Monday, March 31, 2025, at 10:00 AM ET, where the company will spotlight its …
Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19 Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled promising preclinical and Phase 1 data for ratutrelvir, its investigational oral treatment for COVID-19. Presented at the International Conference for …
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced encouraging topline results from preclinical studies evaluating tivoxavir marboxil (TXM) as a potential treatment for H5N1 bird flu. The investigational oral therapy, …
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) shared encouraging findings on its investigational antiviral drug, tivoxavir marboxil (TXM), during the International Society for Antiviral Research (ICAR 2025) in Las Vegas. …
Traws Pharma Unveils Promising Bird Flu Treatment Data Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled encouraging preclinical results for its experimental antiviral drug, tivoxavir marboxil, in combating H5N1 bird flu. Using a ferret model, widely …
Traws Pharma Announces Promising Preclinical Results for Bird Flu Treatment Read More NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) has announced its successful return to compliance with Nasdaq’s minimum stockholders’ equity requirements, ensuring the continuation of its listing on the Nasdaq Capital …
Traws Pharma Regains Nasdaq Compliance, Strengthening Position for 2025 Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced the successful completion of Phase I clinical trials for tivoxavir marboxil, an investigational one-dose treatment aimed at combating H5N1 bird flu. …
Traws Pharma Advances Bird Flu Treatment with Successful Phase I Trial Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has finalized agreements to raise up to $72.6 million to support the development of its promising bird flu treatment, Tivoxavir Marboxil. The …
Traws Pharma Secures $72.6 Million for Bird Flu Treatment Development Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has shared its latest business updates and unaudited financial results for the third quarter ending September 30, 2024. The company is advancing …
Traws Pharma Reports Q3 Financials and Updates on Clinical Advances Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced promising topline results from its Phase 1 study of tivoxavir marboxil, an investigational one-dose influenza treatment. Designed to inhibit the CAP-dependent …
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil Read More